TG Therapeutics (TGTX) Hisse Özeti
Ticari aşamada bir biyofarmasötik şirketi olan TG Therapeutics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda B-hücresi aracılı hastalıklar için yeni tedavilerin satın alınması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 6/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
TGTX Community Fair Values
Create NarrativeSee what 132 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
TG Therapeutics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$56.87 |
| 52 Haftanın En Yüksek Seviyesi | US$59.30 |
| 52 Haftanın En Düşük Seviyesi | US$26.76 |
| Beta | 1.66 |
| 1 Aylık Değişim | 10.02% |
| 3 Aylık Değişim | 6.86% |
| 1 Yıllık Değişim | 75.69% |
| 3 Yıllık Değişim | 522.21% |
| 5 Yıllık Değişim | 76.83% |
| Halka arzdan bu yana değişim | 4,905.04% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Sep 17
TGTX: High Efficacy B Cell Depletion And Subcutaneous Pathway Will Drive Re Rating
Analysts increased their fair value estimate for TG Therapeutics to $86 from $83, citing Street research that highlights strong Briumvi demand, evolving views on long term subcutaneous opportunities, and reaffirmed confidence that high efficacy IV therapies remain central in the B-cell depleting market despite new oral competitors. Analyst Commentary on TG Therapeutics Recent Street research on TG Therapeutics shows a wide range of views, but the most optimistic commentary focuses heavily on the growth runway for Briumvi and the potential of a future subcutaneous formulation.
Anlatı Güncellemesi • Sep 03
TGTX: High Efficacy Multiple Sclerosis Franchise Will Support Future Recovery
Analysts have raised their fair value estimate for TG Therapeutics from about $52 to roughly $70 per share, citing recent price target increases that highlight confidence in Briumvi’s position among high efficacy IV therapies, as well as the additional potential of a future subcutaneous version to expand the company’s market opportunity. Analyst Commentary Recent Street commentary on TG Therapeutics gives you a mix of optimism about Briumvi and its long term franchise potential, along with some clear areas of caution on execution, competition and valuation.
Anlatı Güncellemesi • Aug 17
TGTX: Subcutaneous Data Optimism Will Struggle Against Rising Execution Risks
Analysts have nudged their collective fair value estimate for TG Therapeutics higher, with the modelled price target rising from about $26.92 to $28.81 as they factor in updated views on Briumvi demand, potential revenue upside, and the longer term opportunity from a possible subcutaneous launch. Analyst Commentary Recent Street research on TG Therapeutics shows a split view.Recent updates
Anlatı Güncellemesi • Sep 17
TGTX: High Efficacy B Cell Depletion And Subcutaneous Pathway Will Drive Re Rating
Analysts increased their fair value estimate for TG Therapeutics to $86 from $83, citing Street research that highlights strong Briumvi demand, evolving views on long term subcutaneous opportunities, and reaffirmed confidence that high efficacy IV therapies remain central in the B-cell depleting market despite new oral competitors. Analyst Commentary on TG Therapeutics Recent Street research on TG Therapeutics shows a wide range of views, but the most optimistic commentary focuses heavily on the growth runway for Briumvi and the potential of a future subcutaneous formulation.Anlatı Güncellemesi • Sep 03
TGTX: High Efficacy Multiple Sclerosis Franchise Will Support Future Recovery
Analysts have raised their fair value estimate for TG Therapeutics from about $52 to roughly $70 per share, citing recent price target increases that highlight confidence in Briumvi’s position among high efficacy IV therapies, as well as the additional potential of a future subcutaneous version to expand the company’s market opportunity. Analyst Commentary Recent Street commentary on TG Therapeutics gives you a mix of optimism about Briumvi and its long term franchise potential, along with some clear areas of caution on execution, competition and valuation.Anlatı Güncellemesi • Aug 17
TGTX: Subcutaneous Data Optimism Will Struggle Against Rising Execution Risks
Analysts have nudged their collective fair value estimate for TG Therapeutics higher, with the modelled price target rising from about $26.92 to $28.81 as they factor in updated views on Briumvi demand, potential revenue upside, and the longer term opportunity from a possible subcutaneous launch. Analyst Commentary Recent Street research on TG Therapeutics shows a split view.Anlatı Güncellemesi • Aug 03
TGTX: Elevated Revenue Hurdles Will Restrain Returns Despite Subcutaneous Potential
Analysts have lifted their fair value estimate for TG Therapeutics stock from $20.00 to about $26.92, pointing to stronger Briumvi demand, potential quarterly revenue upside, and a future subcutaneous formulation that could widen the treatment's market and support longer term sales expectations. Analyst Commentary Recent Street commentary on TG Therapeutics highlights a wide spread in opinion on where the stock should trade, even as many analysts point to the same core driver, Briumvi.Anlatı Güncellemesi • Jul 20
TGTX: Elevated Briumvi Expectations And Subcutaneous Data Will Challenge Future Returns
The analyst price target for TG Therapeutics has moved from $17 to $20, as analysts cite updated assumptions for Briumvi. These include expectations around U.S. revenue versus guidance and a more supportive view on the subcutaneous opportunity reflected in their models.Anlatı Güncellemesi • Jul 06
TGTX: Subcutaneous Autoimmune Franchise Is Expected To Drive Future Re Rating
Analysts have raised their fair value estimate for TG Therapeutics to $83, up from $70. They cite updated models that reflect stronger assumptions for subcutaneous Briumvi following recent Phase 1 pharmacokinetic data.Anlatı Güncellemesi • Jun 22
TGTX: Fair Outlook As Late Stage Multiple Sclerosis Data Supports Recovery
Analysts have raised their price target for TG Therapeutics to $51.71 from $44.43, citing updated assumptions around profit margins, discount rate and future P/E that support a higher fair value estimate. What’s in the News for TG Therapeutics TG Therapeutics reported positive Phase 3 ENHANCE trial results showing a single 600 mg Day 1 infusion of BRIUMVI provided bioequivalent exposure to the existing two-step regimen, with safety and MRI outcomes consistent with prior studies, and plans a supplemental BLA filing in the second half of 2026.Analiz Makalesi • Jun 17
TG Therapeutics (TGTX) Stock Looks 14% Overvalued as BRIUMVI Launch Hopes Face Off With Momentum
Recent Performance Snapshot for TG Therapeutics Stock TG Therapeutics (TGTX) has drawn fresh attention after a stretch of strong share price performance, with the stock up 0.5% in the latest session and gaining over the past week, month and past 3 months. At a last close of $50.54, TG Therapeutics now carries a market value of about $7.1 billion, supported by reported revenue of $700.349 million and net income of $461.896 million from its commercial stage biopharmaceutical operations. See our...Anlatı Güncellemesi • Jun 05
TGTX: Expanded Autoimmune Pipeline Will Support A Future Earnings Re Rating
Analysts have raised their fair value estimate for TG Therapeutics by $10 to $70, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels reflected in recent Street research. What's in the News TG Therapeutics reported Q1 2026 total global revenue of about US$205 million, with U.S. BRIUMVI net product revenue of roughly US$195 million and earnings per share of US$0.12 to US$0.17 versus Street expectations of US$0.28 to US$0.30.Anlatı Güncellemesi • May 21
TGTX: Execution Risks And Lower P/E Assumptions Will Pressure Future Upside
Narrative Update on TG Therapeutics The updated analyst price target for TG Therapeutics moves slightly lower to about $17.46 from roughly $17.57 as analysts adjust their assumptions on revenue growth, profit margins and future P/E, while still reflecting recent Street research that includes a $10 upward revision from H.C. Wainwright. Analyst Commentary Behind the modest adjustment in the average price target to about $17.46, bearish analysts remain focused on execution risks and how those could affect the valuation that investors are willing to pay for TG Therapeutics.Anlatı Güncellemesi • Apr 29
TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential
Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.Seeking Alpha • Apr 19
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Summary TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version’s trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets. TGTX enhances financial flexibility with a $750 million term loan, expanded buybacks, and no equity dilution, supporting ongoing growth initiatives. Read the full article on Seeking AlphaAnlatı Güncellemesi • Apr 15
TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations
Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.Anlatı Güncellemesi • Mar 31
TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery
Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.Anlatı Güncellemesi • Mar 17
TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Drives Confidence
Analysts recently adjusted their price targets for TG Therapeutics in a mixed way, with one firm cutting its target by $3 while others raised theirs by $2 and $2. These changes reflect updated views on sector conditions, access to capital, M&A activity and company specific data catalysts.Anlatı Güncellemesi • Mar 03
TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Supports Upside
Analysts have nudged their price targets on TG Therapeutics in both directions recently, with moves such as a $3 trim at one firm and a $2 lift at another. These changes reflect updated views on discount rates, revenue growth assumptions, profit margins and future P/E, rather than a wholesale shift in the $44.43 fair value estimate used in this model.Anlatı Güncellemesi • Feb 17
TGTX: Shares Should Rebound As Revenue Outlook Supports Mixed Street Views
Analysts have made only a modest adjustment to their TG Therapeutics price targets, reflecting a slightly higher assumed discount rate and marginally lower future P/E expectations, while maintaining a consistent fair value estimate near $44 per share. Analyst Commentary Recent Street research on TG Therapeutics has been mixed, with some firms lifting price targets and others trimming them.Anlatı Güncellemesi • Feb 02
TGTX: Shares Should Rebound As Mixed Street Views Contrast With Strong Revenue Outlook
Analysts have adjusted their blended price target on TG Therapeutics slightly lower, trimming fair value by about $0.43 to reflect updated assumptions around growth, margins and future P/E following a mix of recent target revisions from major firms. Analyst Commentary Recent Street research on TG Therapeutics reflects a mix of optimism on the setup for biotech and specific caution around the company’s execution and valuation, which is feeding into the modest trim in the blended price target.Anlatı Güncellemesi • Jan 19
TGTX: Shares Should Rebound As Revenue Outlook Strengthens On Updated Guidance
Narrative Update Analysts have nudged their price target for TG Therapeutics higher to about $44.86, up from roughly $44.29. This reflects updated earnings models that incorporate slightly higher profit margin assumptions, a modestly adjusted discount rate and a small change to expected future P/E levels following recent Street research, including target increases from BofA, Goldman Sachs and JPMorgan.Anlatı Güncellemesi • Jan 05
TGTX: Higher JPMorgan Price View Will Likely Overstate Future Earnings Delivery
TG Therapeutics' analyst price target has moved higher, with a recent US$3 increase to US$49 as analysts refreshed their models after the latest earnings update. Analyst Commentary The latest move to a US$49 price target from JPMorgan signals that at least one major firm has refreshed its view following the recent earnings update, with a focus on updated assumptions in its valuation model.Anlatı Güncellemesi • Dec 22
TGTX: Higher Earnings Visibility Will Support A Re-Rating Over Time
Analysts have lifted their price target on TG Therapeutics shares, raising fair value by about $7 per share to $60, as updated post earnings models factor in a higher future P/E multiple despite slightly lower growth and margin assumptions. Analyst Commentary Following the latest earnings update, bullish analysts are increasingly highlighting TG Therapeutics as a beneficiary of improving fundamentals and greater earnings visibility, which they see as supporting a higher valuation range over the medium term.Anlatı Güncellemesi • Dec 08
TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches
Analysts have modestly raised their blended price target for TG Therapeutics, reflecting increased confidence in multi year Briumvi growth and updated post earnings models that point to a path toward more than $1 billion in annual sales. Analyst Commentary Recent Street updates reflect a predominantly constructive stance on TG Therapeutics, with upwardly revised price targets and reinforced positive ratings following the latest earnings update.Anlatı Güncellemesi • Nov 24
TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip
Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.Anlatı Güncellemesi • Nov 05
TGTX: Shares Will Likely See Renewed Momentum With Expanding U.S. Drug Adoption
Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.Analiz Makalesi • Oct 23
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Anlatı Güncellemesi • Oct 22
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
Narrative Update on TG Therapeutics Analysts have raised their price target for TG Therapeutics by $2 to $55. They cite expectations for sustained multi-year sales growth, supported by strong prospects for Briumvi in the U.S. market.Anlatı Güncellemesi • Oct 08
A Subcutaneous Launch Will Unlock The Anti-CD20 MS Market
Analysts have raised their price target for TG Therapeutics from $40.50 to $43.57, citing expectations of sustained Briumvi sales growth and an improved revenue outlook. Analyst Commentary Recent Street research highlights a range of perspectives regarding TG Therapeutics, with particular focus on Briumvi's market performance and growth trajectory.Analiz Makalesi • Sep 30
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Mar 14
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Summary TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy. TG Therapeutics' strong cash position and ongoing Briumvi revenues are expected to fund operations and potential portfolio expansion, despite risks from trial data and international approvals. Read the full article on Seeking AlphaHissedar Getirileri
| TGTX | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 5.5% | 1.2% | 0.5% |
| 1Y | 75.7% | 37.1% | 12.0% |
Getiri vs. Endüstri: TGTX geçen yıl % 37.1 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: TGTX geçen yıl % 12 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| TGTX volatility | |
|---|---|
| TGTX Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: TGTX son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: TGTX 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1993 | 399 | Mike Weiss | www.tgtherapeutics.com |
Ticari aşamada bir biyofarmasötik şirketi olan TG Therapeutics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda B-hücresi aracılı hastalıklar için yeni tedavilerin edinilmesi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, yetişkinlerde klinik olarak izole sendrom, relapsing-remitting hastalık ve aktif sekonder progresif hastalık dahil olmak üzere relapsing multipl skleroz (RMS) formları olan yetişkin hastaların tedavisi için bir anti-CD20 monoklonal antikoru olan BRIUMVI'yi sunmaktadır. Şirketin geliştirme hattı, nükseden MS tedavisi için glikomühendislik ürünü anti-CD20 mAb olan Ublituximab IV'ü; in vitro kinaz taramasında BTK'ya seçicilik sergileyen, oral olarak temin edilebilen ve kovalent bağlı bir Bruton tirozin kinaz (BTK) inhibitörü olan TG-1701'i ve bispesifik bir CD47 ve CD19 antikoru olan TG-1801'i içermektedir.
TG Therapeutics, Inc. Temel Bilgiler Özeti
| TGTX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$8.01b |
| Kazançlar(TTM) | US$441.49m |
| Gelir(TTM) | US$799.54m |
18.3x
F/K Oranı10.1x
P/S OranıTGTX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| TGTX gelir tablosu (TTM) | |
|---|---|
| Gelir | US$799.54m |
| Gelir Maliyeti | US$140.94m |
| Brüt Kâr | US$658.60m |
| Diğer Giderler | US$217.11m |
| Kazançlar | US$441.49m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 3.11 |
| Brüt Marj | 82.37% |
| Net Kâr Marjı | 55.22% |
| Borç/Özkaynak Oranı | 123.4% |
TGTX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/18 03:11 |
| Gün Sonu Hisse Fiyatı | 2026/09/18 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
TG Therapeutics, Inc. 18 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |